

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Cancelled).
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Currently amended) An isolated agonist anti-trkC antibody comprising:
 - (a) heavy chain CDRs (CDRHs) comprising:
 - (i) a CDRH1 of the formula GYTFTSYXaaXaaH (SEQ ID NO:16), wherein Xaa at position 8 is R or W, and Xaa at position 9 is I, L, R, or M;
 - (ii) a CDRH2 of the formula EIYPSNXaaRTNYNEKFXaaS (SEQ ID NO:17), wherein Xaa at position 7 is A, T, S, or G; and Xaa at position 16 is K or E; and
 - (iii) a CDRH3 of the formula KYYYGNXaaXaaRSWYFDV (SEQ ID NO:18), ~~(a) a CDR1 of the formula RASESXaaDXaaYGISFXaaXaa (SEQ ID NO:19)~~, wherein Xaa at position 6 is I or V; Xaa at position 8 is N or S; Xaa at position 14 is L or M; Xaa at position 15 is A, T, or N;
 - (b) ~~a CDR2 of the formula AASNXaaGS (SEQ ID NO:20)~~, wherein Xaa at position 5 is R, L, or Q; and
 - (c) ~~a CDR3 of the formula QQSKXaaVPRT (SEQ ID NO:21)~~, wherein Xaa at position 5 is T, A, S, or E;

wherein the agonist anti-trkC antibody is not an antibody comprising a light chain CDRs comprising a CDR1 region of SEQ ID NO:25, a CDR2 region of SEQ ID NO:26, and a CDR3 region of SEQ ID NO:27 wherein Xaa at position 7 is T or S; wherein Xaa at position 8 is R, Q, K, S, or Y; and
 - (b) light chain CDRs (CDRL) comprising:

(i) a CDRL₁ of the formula RASESXaaDXaaYGISFXaaXaa (SEQ ID NO:19), wherein Xaa at position 6 is I or V; Xaa at position 8 is N or S; Xaa at position 14 is L or M; Xaa at position 15 is A, T, or N;

(ii) a CDRL₂ of the formula AASN_{Xaa}GS (SEQ ID NO:20), wherein Xaa at position 5 is R, L, or Q; and

(iii) a CDRL₃ of the formula QQSKXaaVPRT (SEQ ID NO:21), wherein Xaa at position 5 is T, A, S, or E;
wherein the agonist anti-trkC antibody is not an antibody comprising (a) a heavy chain CDRs comprising a CDRH₁ region of SEQ ID NO:22, a CDRH₂ region of SEQ ID NO:23, and a CDRH₃ region of SEQ ID NO:24; and (b) a light chain CDRs comprising a CDRL₁ region of SEQ ID NO:25, a CDRL₂ region of SEQ ID NO:26, and a CDRL₃ region of SEQ ID NO:27.

6. (Previously presented) The isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody binds human trkC.

7. (Previously presented) The isolated agonist anti-trkC antibody of claim 6, wherein the agonist anti-trkC antibody binds to human trkC with a K_D less than about 5 nM.

8. (Previously presented) The isolated agonist anti-trkC antibody of claim 6, wherein the agonist anti-trkC antibody further binds rodent trkC.

9. (Previously presented) The isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody is a monoclonal antibody.

10. (Previously amended) The isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody is a humanized antibody.

11. (Currently amended) The isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody comprises a heavy chain ~~variable region~~ CDRs (CDRH) comprising:

- (a) a CDRH₁ region of SEQ ID NO:4;
- (b) a CDRH₂ region of SEQ ID NO:5; and
- (c) a CDRH₃ region of SEQ ID NO:6.

12. (Previously presented) The isolated agonist anti-trkC antibody of claim 11, wherein the heavy chain variable region consists of the sequence of SEQ ID NO:1.

13. (Previously presented) The isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody comprises a light chain ~~variable region~~ CDRs (CDRL) comprising:

- (a) a CDRL₁ region of SEQ ID NO:7;
- (b) a CDRL₂ region of SEQ ID NO:8; and
- (c) a CDRL₃ region of SEQ ID NO:9.

14. (Previously presented) The isolated agonist anti-trkC antibody of claim 13, wherein the light chain variable region consists of the sequence of SEQ ID NO:2.

15. (Currently amended) An isolated agonist anti-trkC antibody of claim 5, wherein the agonist anti-trkC antibody comprises

- (a) ~~a heavy chain variable region CDRHs~~ comprising:
 - (i) a CDRH₁ region of SEQ ID NO:4;
 - (ii) a CDRH₂ region of SEQ ID NO:5; and
 - (iii) a CDRH₃ region of SEQ ID NO:6; and
- (b) ~~a light chain variable region CDRLs~~ comprising:
 - (i) a CDRL₁ region of SEQ ID NO:7;
 - (b) a CDRL₂ region of SEQ ID NO:8; and
 - (c) a CDRL₃ region of SEQ ID NO:9.

16. (Previously presented) The isolated agonist anti-trkC antibody of claim 15, wherein the heavy chain variable region consists of SEQ ID NO:1, and the light chain variable region consists of the sequence of SEQ ID NO:2.
17. (Previously presented) The isolated agonist anti-trkC antibody of claim 15, wherein the heavy chain consists of the sequence of SEQ ID NO:28, and the light chain variable region consists of the sequence of SEQ ID NO:29.
18. (Withdrawn) A nucleic acid encoding an agonist anti-trkC antibody of any of claims 1-17.
19. (Withdrawn) The nucleic acid of claim 18, wherein the nucleic acid comprises the sequence of SEQ ID NO:12 encoding the heavy chain variable region of the agonist anti-trkC antibody, and the sequence of SEQ ID NO:10 encoding the light chain variable region of the agonist anti-trkC antibody.
20. (Withdrawn) The nucleic acid of claim 19, wherein the nucleic acid comprises the sequence of SEQ ID NO:13 encoding the heavy chain of the agonist anti-trkC antibody, and the sequence of SEQ ID NO:11 encoding the light chain variable region of the agonist anti-trkC antibody.
21. (Withdrawn) A vector comprising the nucleic acid of claim 18.
22. (Withdrawn) A host cell comprising the nucleic acid of claim 18.
23. (Previously presented) A pharmaceutical composition comprising (a) an effective amount of the agonist anti-trkC antibody of claim 5 and (b) a pharmaceutical acceptable excipient.

24. (Previously presented) A kit comprising the agonist anti-trkC antibody of claim 5.

25. (Withdrawn) A method of making an agonist anti-trkC antibody, said method comprising expressing a polynucleotide encoding the agonist anti-trkC antibody of any of claims 1-17 in a host cell.

26. (Currently amended) An isolated polypeptide that binds to trkC, comprising:

- (a) a CDR_{H1} of the formula GYTFTSYXaaXaaH (SEQ ID NO:16), wherein Xaa at position 8 is R or W, and Xaa at position 9 is I, L, R, or M;
- (b) a CDR_{H2} of the formula EIYPSNXaaRTNYNEKFXaaS (SEQ ID NO:17), wherein Xaa at position 7 is A, T, S, or G; and Xaa at position 16 is K or E; and
- (c) a CDR_{H3} of the formula KYYYGNXaaXaaRSWYFDV (SEQ ID NO:18), wherein Xaa at position 7 is T or S; wherein Xaa at position 8 is R, Q, K, S, or Y; wherein the polypeptide is not a polypeptide comprising CDR_{Hs} comprising a CDR_{H1} region of SEQ ID NO:22, a CDR_{H2} region of SEQ ID NO:23, and a CDR_{H3} region of SEQ ID NO:24; and further comprising:
 - (d) a CDR4 CDRL1 of the formula RASESXaaDXaaYGISFXaaXaa (SEQ ID NO:19), wherein Xaa at position 6 is I or V; Xaa at position 8 is N or S; Xaa at position 14 is L or M; Xaa at position 15 is A, T, or N;
 - (e) a CDR5 CDRL2 of the formula AASNXaaGS (SEQ ID NO:20), wherein Xaa at position 5 is R, L, or Q; and
 - (f) a CDR6 CDRL3 of the formula QQSKXaaVPRT (SEQ ID NO:21), wherein Xaa at position 5 is T, A, S, or E;
wherein the polypeptide is not a polypeptide comprising CDRLs comprising a CDRL₁ region of SEQ ID NO:25, a CDRL₂ region of SEQ ID NO:26, and a CDRL₃ region of SEQ ID NO:27.

27. (Cancelled).